BMJ 2000;320:985-986 ( 8 April )

General Practice

Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study

Martin J Landray, lecturer in clinical pharmacology ^a,  Richard Lehman, general practice principal ^b,  Ian Arnold, consultant cardiologist ^c. 

^a Division of Medical Sciences, University of Birmingham, Birmingham BI5 2TH, ^b Hightown Surgery, Banbury OX18 9DB, ^c Department of Medicine, Horton Hospital, Oxford Radcliffe Hospitals NHS Trust, Banbury OX16 9AL

Correspondence to: R Lehman lehman{at}hightownl.demon.co.uk

The prevalence of heart failure is increasing.¹ Patients usually present to their general practitioner but a definitive diagnosis of left ventricular systolic dysfunction can only be achieved by cardiac imaging. Measuring plasma concentrations of brain natriuretic peptide has been advocated as a screening test that might reduce demands on cardiological services.²

We report the results of a community based study designed to investigate the effectiveness of measuring brain natriuretic peptide to diagnose left ventricular systolic dysfunction. The study was approved by the local research ethics committee.

	Participants, methods, and results

Top Participants, methods, and... Comment References

General practitioners were invited to refer patients with suspected heart failure to our clinic. The results of transthoracic echocardiography were reported by a single, experienced observer (IA). Ischaemia was diagnosed if Q waves, bundle branch block, T wave inversions, or left ventricular hypertrophy were present on an electrocardiogram. Evidence of heart failure on a chest radiograph was defined as the presence of pulmonary oedema or cardiomegaly. Concentrations of brain natriuretic peptide were measured by immunoradiometric assay (Shionoria assay, Shionogi, Osaka, Japan) of plasma stored at 70°C. A concentration >17.9 pg/ml was considered abnormal based on the results of a large study of left ventricular systolic dysfunction.³

Altogether, 126 patients (68 men) with a mean age of 74.4 (SD 8.9) years were included in the study. Concentrations of the peptide were raised in the 40 patients with left ventricular systolic dysfunction (median concentration 79.4 pg/ml, interquartile range 35.9-151.0) compared with those with normal ventricular systolic function (26.7 pg/ml, 12.2-54.3; P<0.001). A concentration >17.9 pg/ml had a sensitivity of 88% and specificity of 34%. Choosing different cut points did not improve the predictive characteristics: at 10 pg/ml sensitivity was 92% but specificity was 18%, and at 76 pg/ml sensitivity was 66% and specificity 87%.

View this table: [in this window] [in a new window]   Likelihood ratios for screening tests for left ventricular systolic dysfunction. Any combination of tests is defined as being positive if any of the individual components are positive

The prior probability that a disease exists (its prevalence) and the extent to which a test result alters the chance of the disease existing determine whether further investigation is needed; this is the likelihood ratio of positive and negative tests. In the case of heart failure it is unlikely that a single positive test result will remove the need for further cardiac imaging before treatment is started. In contrast, a negative result may give a low posterior probability of disease so that further investigations are unnecessary.

The prevalence (or prior probability) of left ventricular systolic dysfunction in this study was 32%; this is consistent with that reported in other studies.⁴ The likelihood ratio for a patient without a history of myocardial infarction, with negative results on chest radiography and electrocardiography, and with concentrations of brain natriuretic peptide below the cut off, individually and in combination, are shown in the table. Measuring the concentration of brain natriuretic peptide is the test with the lowest likelihood ratio for a negative test; thus it is the most useful. However, to be useful in clinical practice, this test must provide additional diagnostic information over that given by investigations that are more readily available, which in combination yield a minimum posterior probability of 20%. Adding a test for brain natriuretic peptide to the determination of a patient's history of myocardial infarction in the diagnostic screening process reduces the posterior probability to 15%.

	Comment

Top Participants, methods, and... Comment References

There seems to be a small diagnostic advantage to measuring brain natriuretic peptide in addition to performing routine investigations. However, given the therapeutic and prognostic importance of correct diagnosis, most clinicians would find a 1 in 7 chance of left ventricular systolic dysfunction unacceptably high in a patient who has not been referred for echocardiography.

Recruitment to this study relied on the general practitioners making a provisional diagnosis of suspected heart failure, and results may be different in other settings, such as population based screening for asymptomatic left ventricular systolic dysfunction. Nevertheless this study suggests that introducing       routine measurement of the plasma concentration of brain natriuretic peptide would be unlikely to improve the diagnosis of symptomatic left ventricular systolic dysfunction in the community.

	Acknowledgments

We would like to thank Chris Teideman, Tim Lancaster and Alice Fuller for their help and support.

Contributors: IA and RL obtained funding for the study. All three authors designed the study protocol. IA and MJL ran the clinic for patients with suspected heart failure. MJL performed the statistical analysis and wrote the first draft of the paper. All three authors approved the final draft of the paper. Brain natriuretic peptide was measured by Dr M Morton, MRC Clinical Research Initiative in Heart Failure, University of Glasgow. RL will act as guarantor for the study.

	Footnotes

Funding: This study was supported by a grant from the Oxford Region NHS research and development fund.

Competing interests: None declared.

	References

Top Participants, methods, and... Comment References

1.	Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998; 19(suppl L): 2-8L.
2.	Struthers AD. Further defining the role for natriuretic peptide levels in clinical practice. Eur Heart J 1999; 20: 712-714.
3.	McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13[CrossRef][Medline].
4.	Wheeldon NM, MacDonald TM, Flucker CF, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86: 17-23[Abstract/Free Full Text].

(Accepted 13 December 1999)

---

© BMJ 2000
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study

Frans H Rutten, Karel G M Moons, Maarten-Jan M Cramer, Diederick E Grobbee, Nicolaas P A Zuithoff, Jan-Willem J Lammers, and Arno W Hoes
BMJ 2005 331: 1379. [Abstract] [Full Text] [PDF]

What happened to evidence in NICE guidance on heart failure?

John Robson
BMJ 2003 327: 932. [Extract] [Full Text]

Predicting left ventricular systolic dysfunction

Frank Dobbs, Allan D Struthers, Martin J Landray, Richard Lehman, and Ian Arnold
BMJ 2000 321: 895. [Extract] [Full Text]

This article has been cited by other articles:

• Fahey, T, Jeyaseelan, S, McCowan, C, Carr, E, Goudie, B., Pringle, S., Donnan, P., Sullivan, F., Struthers, A. (2007). Diagnosis of left ventricular systolic dysfunction (LVSD): development and validation of a clinical prediction rule in primary care. Fam Pract 24: 628-635 [Abstract] [Full text]  
• Rutten, F. H., Cramer, M.-J. M., Zuithoff, N. P.A., Lammers, J.-W. J., Verweij, W., Grobbee, D. E., Hoes, A. W. (2007). Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 9: 651-659 [Abstract] [Full text]  
• Latour-Perez, J., Coves-Orts, F. J., Abad-Terrado, C., Abraira, V., Zamora, J. (2006). Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: A systematic review. Eur J Heart Fail 8: 390-399 [Abstract] [Full text]  
• Battaglia, M., Pewsner, D., Juni, P., Egger, M., Bucher, H. C., Bachmann, L. M. (2006). Accuracy of B-type natriuretic Peptide tests to exclude congestive heart failure: systematic review of test accuracy studies.. Arch Intern Med 166: 1073-1080 [Abstract] [Full text]  
• Rutten, F. H, Moons, K. G M, Cramer, M.-J. M, Grobbee, D. E, Zuithoff, N. P A, Lammers, J.-W. J, Hoes, A. W (2005). Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 331: 1379- [Abstract] [Full text]  
• Adlam, D., Silcocks, P., Sparrow, N. (2005). Using BNP to develop a risk score for heart failure in primary care. Eur Heart J 26: 1086-1093 [Abstract] [Full text]  
• Gluud, C., Gluud, L. L. (2005). Evidence based diagnostics. BMJ 330: 724-726 [Full text]  
• Doust, J. A., Glasziou, P. P., Pietrzak, E., Dobson, A. J. (2004). A Systematic Review of the Diagnostic Accuracy of Natriuretic Peptides for Heart Failure. Arch Intern Med 164: 1978-1984 [Abstract] [Full text]  
• Hammerer-Lercher, A., Ludwig, W., Falkensammer, G., Muller, S., Neubauer, E., Puschendorf, B., Pachinger, O., Mair, J. (2004). Natriuretic Peptides as Markers of Mild Forms of Left Ventricular Dysfunction: Effects of Assays on Diagnostic Performance of Markers. Clin. Chem. 50: 1174-1183 [Abstract] [Full text]  
• Ng, L. L., Loke, I., Davies, J. E., Khunti, K., Stone, M., Abrams, K. R., Chin, D. T., Squire, I. B. (2003). Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 5: 775-782 [Abstract] [Full text]  
• Wright, S. P., Doughty, R. N., Pearl, A., Gamble, G. D., Whalley, G. A., Walsh, H. J., Gordon, G., Bagg, W., Oxenham, H., Yandle, T., Richards, M., Sharpe, N. (2003). Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 42: 1793-1800 [Abstract] [Full text]  
• Robson, J. (2003). What happened to evidence in NICE guidance on heart failure?. BMJ 327: 932-932 [Full text]  
• Wang, T. J., Levy, D., Benjamin, E. J., Vasan, R. S. (2003). The Epidemiology of "Asymptomatic" Left Ventricular Systolic Dysfunction: Implications for Screening. ANN INTERN MED 138: 907-916 [Abstract] [Full text]  
• Ruskoaho, H. (2003). Cardiac Hormones as Diagnostic Tools in Heart Failure. Endocr. Rev. 24: 341-356 [Abstract] [Full text]  
• Rutten, F. H., Grobbee, D. E., Hoes, A. W. (2003). Diagnosis and management of heart failure: a questionnaire among general practitioners and cardiologists. Eur J Heart Fail 5: 345-348 [Full text]  
• Nielsen, O. W., McDonagh, T. A., Robb, S. D., Dargie, H. J. (2003). Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population. J Am Coll Cardiol 41: 113-120 [Abstract] [Full text]  
• Colli, A., Fraquelli, M., Conte, D., Hassan, Y., Shapira, A. R., Hassan, S., Foote, R. S., Pearlman, J. D., Maisel, A. S., Clopton, P., McCullough, P. A. (2002). B-Type Natriuretic Peptide in Heart Failure. NEJM 347: 1976-1978 [Full text]  
• Hobbs, F D R, Davis, R C, Roalfe, A K, Hare, R, Davies, M K, Kenkre, J E (2002). Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324: 1498-1498 [Abstract] [Full text]  
• Sackett, D L, Haynes, R B (2002). Evidence base of clinical diagnosis: The architecture of diagnostic research. BMJ 324: 539-541 [Full text]  
• Boomsma, F., van den Meiracker, A. H. (2001). Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 51: 442-449 [Full text]  
• Davidson, C., Hobbs, R. (2000). Can heart failure be diagnosed in primary care?. BMJ 321: 1414b-1414 [Full text]  
• Dobbs, F., Struthers, A. D, Landray, M. J, Lehman, R., Arnold, I. (2000). Predicting left ventricular systolic dysfunction. BMJ 321: 895-895 [Full text]  
• Hobbs, R. (2000). Can heart failure be diagnosed in primary care?. BMJ 321: 188-189 [Full text]  

Rapid Responses:

Read all Rapid Responses

The BMJ should standardise its units

Wai-Ching Leung
bmj.com, 9 Apr 2000 [Full text]

Predicting ventricular systolic dysfunction

Frank Dobbs
bmj.com, 14 Apr 2000 [Full text]

Patient characteristics in study of BNP for identifying LV dysfunction

George A Heckman
bmj.com, 4 Apr 2002 [Full text]

Online poll

Find out more on doc2doc >>